甲泼尼龙与COVID-19肺炎60天住院生存率
匹配样本中,未用组死亡26%,低剂量组31.9%,高剂量组55.2%。多因素Cox回归显示甲泼尼龙与死亡率降低相关(HR 0.40,95%CI 0.27-0.59),但高剂量无额外获益且与更高死亡率相关;低剂量疗程7-14天优于≤7天(HR 0.45,95%CI 0.22-0.91),>14天无额外获益。
要点
- 倾向性匹配样本中,高剂量甲泼尼龙组死亡率55.2%,高于未用组26%和低剂量组31.9%。
- 多因素Cox回归显示甲泼尼龙与死亡率降低相关(HR 0.40,95%CI 0.27-0.59,p<0.001),但高剂量无额外获益。
- 低剂量甲泼尼龙疗程7-14天较≤7天降低死亡率(HR 0.45,95%CI 0.22-0.91,p=0.0273),>14天无额外获益(HR 1.27,95%CI 0.60-2.69,p=0.5434)。
- 甲泼尼龙联合托珠单抗较单药治疗与死亡率降低相关(p<0.0116)。
- 养老院居住者、冠心病、有创机械通气为独立死亡危险因素。
适用人群与场景
- 倾向性匹配队列分析,比较接受甲泼尼龙与未接受甲泼尼龙的患者。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 低剂量甲泼尼龙:原文未提及具体剂量、给药途径和频次。
- 高剂量甲泼尼龙:原文未提及具体剂量、给药途径和频次。
- 低剂量甲泼尼龙疗程7-14天与降低死亡率相关,≤7天或>14天无额外获益或获益减少。
- 甲泼尼龙联合托珠单抗较单药治疗与死亡率降低相关(p<0.0116)。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 匹配样本中,未用甲泼尼龙组死亡99/380(26%),低剂量组死亡69/215(31.9%),高剂量组死亡74/164(55.2%)。
- 多因素Cox回归显示甲泼尼龙与死亡率降低相关(HR 0.40,95%CI 0.27-0.59,p<0.001),高剂量无额外获益。
- 低剂量甲泼尼龙疗程7-14天较≤7天降低死亡率(HR 0.45,95%CI 0.22-0.91,p=0.0273),>14天无额外获益(HR 1.27,95%CI 0.60-2.69,p=0.5434)。
- 甲泼尼龙联合托珠单抗较单药治疗与死亡率降低相关(p<0.0116)。
证据类型、等级与局限
- 证据类型:多中心回顾性倾向性匹配队列研究。
- 局限:回顾性设计、单国家多中心、样本量有限、可能存在未测量混杂。
对床旁实践的改变
- 对于住院COVID-19肺炎患者,低剂量甲泼尼龙(症状出现>7天启用、疗程7-14天)可能与降低死亡率相关,高剂量可能与死亡率升高相关。
- 不推荐高剂量甲泼尼龙;疗程不宜超过14天。
- 甲泼尼龙联合托珠单抗可能较单药治疗降低死亡率,但需进一步验证。
- 养老院居住者、冠心病、有创机械通气患者死亡风险更高,应加强监护。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine methylprednisolone's dose, duration, and administration from onset of symptoms and association with 60 days in hospital survival of coronavirus disease 2019 pneumonia.
DESIGN: Cohort study.
SETTING: Thirteen hospitals in New Jersey, United States during March to June 2020.
PATIENTS: Seven-hundred fifty-nine hospitalized coronavirus disease 2019 patients.
INTERVENTIONS: We performed a propensity matched cohort study between patients who received methylprednisolone and no methylprednisolone. Patients in the methylprednisolone group were further differentiated into dose (high dose and low dose), duration, and administration from onset of symptoms.
MEASUREMENTS AND MAIN RESULTS: In the propensity matched sample, 99 out of 380 (26%) in no methylprednisolone, 69 out of 215 (31.9%) in low-dose methylprednisolone, and 74 out of 164 (55.2%) high-dose methylprednisolone expired. Overall median survival for no methylprednisolone (25.0 d), low-dose methylprednisolone (39.0 d), high-dose methylprednisolone (20.0 d), less than or equal to 7 days duration (19.0 d), 7-14 days duration (30.0 d), greater than 14 days duration (44.0 d), onset of symptoms less than or equal to 7 days (20.0 d), and onset of symptoms 7-14 days (27.0 d) were statistically significant (log-rank p ≤ 0.001). Multivariate Cox regression showed nursing home residents, coronary artery disease, and invasive mechanical ventilation were independently associated with mortality. Methylprednisolone was associated with reduced mortality compared with no methylprednisolone (hazard ratio, 0.40; 95% CI, 0.27-0.59; p < 0.001) but no added benefit with high dose. Low-dose methylprednisolone for 7-14 days was associated with reduced mortality compared with less than or equal to 7 days (hazard ratio, 0.45; 95% CI, 0.22-0.91; p = 0.0273), and no additional benefit if greater than 14 days (hazard ratio, 1.27; 95% CI, 0.60-2.69; p = 0.5434). Combination therapy with tocilizumab was associated with reduced mortality over monotherapy (p < 0.0116).
CONCLUSIONS: Low-dose methylprednisolone was associated with reduced mortality if given greater than 7 days from onset of symptoms, and no additional benefit greater than 14 days. High dose was associated with higher mortality.
参考来源
- Go RC, Shah R, Nyirenda T, et al. Methylprednisolone and 60 Days in Hospital Survival in Coronavirus Disease 2019 Pneumonia. Crit Care Explor. 2021. PMID: 34291223. doi:10.1097/CCE.0000000000000493
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。